Malignancy is the fourth leading cause of death in persons aged 1 to 19 years. The success of the pediatric oncology cooperative group clinical trials has allowed a systematic approach to the treatment of relatively rare malignancies. Each trial builds on previous results in terms of both survival and toxicity. This article will discuss the current treatment regimens for several of the more common pediatric malignancies and their long-term complications developed through this process.
Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.
2.
Shochat SJ, Fremgen AM, Murphy SB, et al. Childhood cancer: patterns of protocol participation in a national survey. CA Cancer J Clin. 2001;51:119-130.
3.
Felix CA, Lange BJ. Leukemia in infants. Oncologist. 1999;4:225-240.
4.
Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood. 2000;96(1):24-33.
5.
Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Sem Oncol. 1985;12:131-148.
6.
Pui CH, Simone JV, Hancock ML, et al. Impact of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St. Jude total therapy study X. Leukemia. 1992;6:150-157.
7.
Henze G, Langermann HJ, Ritter J.Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM study group. Haematol Blut Transfus. 1981;26:87-93.
8.
Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children’s Cancer Study Group Study CCG 106. J Clin Oncol. 1993;11:2234-2242.
9.
Tubergen DG, Gilchrist GS, O’Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children’s Cancer Group Phase III trial. J Clin Oncol. 1993;11:527-537.
10.
Lange BJ, Bostrom BC, Cherlow JM, et al. Double delayed intensification improves event-free survival for children with intermediate risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. In press.
11.
Nesbit M, Sather H, Robison L, et al. Randomized study of 3 years vs 5 years of chemotherapy in childhood acute lymphoblastic leukemia. J Clin Oncol. 1983;1:308-316.
12.
Miller DR, Leikin SL, Albo VC, et al. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Study Group. J Clin Oncol. 1989;7:73-79.
13.
Gayon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1999;457:593-605.
14.
Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
15.
Conter V, Arico M, Valsecchi MG, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. J Clin Oncol. 1995;13:2497-2502.
16.
Meadows A, Massari D, Fergusson J, et al. Declines in IQ scores and cognitive dysfunctions in children with acute lymphoblastic leukemia treated with cranial irradiation. Lancet. 1981;10:1015-1018.
17.
Neglia J, Meadows A, Robison L, et al. Second neoplasms after acute lymphoblastic leukemia in children. N Engl J Med. 1991;325:1330-1336.
18.
Relling RV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34-39.
19.
Nachman JB, Sather HN, Sensel MG, et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
20.
Buchanan GR, Rivera GK, Boyett JM, et al. Reinduction therapy in 297 children with acute lymphocytic leukemia in first bone marrow relapse: a Pediatric Oncology Group study. Blood. 1988;72:1286-1292.
21.
Leahey AM, Bunin NJ, Belasco JB, et al. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Med Pediatr Oncol. 2000;34:313-318.
22.
Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994;331:1253-1258.
23.
Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
24.
Pui C, Behm F, Raimondi S, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321:136-142.
25.
Mattano LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000;18(18):3262-3272.
26.
Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525-1532.
27.
Lipschultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
28.
Langmuir PB, Aplenc RA, Lange BJ. Acute myeloid leukaemia in children. Balliere’s Clin Haematol. 2001;14(1):77-93.
29.
Ravindranath Y, Abella E, Krischer J, et al. Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on pediatric oncology group AML study 8498. Blood. 1992;80:2210-2214.
30.
Craze JL, Harrison G, Wheatley K, et al. Improved outcome of acute myeloid leukemia in Down’s syndrome. Arch Dis Child. 1999;81:32-37.
31.
Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
32.
Woods WG, Nesbit ME, Buckley J, et al. Correlation of chromosome abnormalities with patient characteristics, histologic subtype, and induction success in children with acute nonmyelocytic leukemia. J Clin Oncol. 1985;3(1):3-11.
33.
Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1973-1997, National Cancer Institute. NIH Pub. No. 00-2789. Bethesda, MD, 2000.
34.
Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Oncology Group. Blood. 1996;87:4979-4989.
35.
Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children’s Cancer Group. Blood. 2001;97:56-62.
36.
Wells R, Woods W, Lampkin B, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children’s Cancer Group 213P. J Clin Oncol. 1993;11(3):538-545.
37.
Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996;334:1428-1434.
38.
Michel G, Leverger G, Leblanc T, et al. Allogeneic bone marrow transplantation versus aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant. 1996;17:191-196.
39.
Weisman SJ, Scoopo FJ, Johnson GM, et al. Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol. 1990;8:453-459.
40.
Leung W, Hudson MM, Strickland DK, et al. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol. 2000;18:3273-3279.
41.
Hudson MM, Donaldson SS. Hodgkin’s disease. Pediatr Clin North Am. 1997;44:891-907.
42.
Josting A, Wolf J, Diehl V.Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol. 2000;12:403-411.
43.
Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435-2443.
44.
Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s lymphoma in childhood. N Engl J Med1996;334:1238-1248.
45.
Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416-421.
46.
Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children’s Cancer Group Study 5912. J Clin Oncol. 2001;19:2390-2396.
47.
Siffert J, Greenleaf M, Mannis R, Allen J.Pediatric brain tumors. Child Adol Pysch Clin North Am. 1999;8(4):879-903.
48.
Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001;19:1802-1808.
49.
Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342-352.
50.
Womer RB, Daller RT, Fenton JG, Miser JS. Granuloxyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur J Cancer. 2000;36:87-94.
51.
Bramwell VHC. The role of chemotherapy in osteogenic sarcoma. Crit Rev Oncol Hematol. 1995;20:61-85.
52.
Green DM, Breslow NE, Evans I, et al. The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study. Am J Pediatr Hematol Oncol. 1994;16(3):207-212.
53.
Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol. 2001;19:1926-1934.
54.
Green DM, Donckerwolcke R, Evans AE, D’Angio GJ. Late effects of treatment for Wilms Tumor. Hematol Oncol Clin North Am. 1995;9(6):1317-1327.
55.
Albright AL. Pediatric brain tumors. CA Cancer J Clin. 1993;43:272-288.
56.
Freeman CR, Perilongo G.Chemotherapy for brain stem gliomas. Child Nerv Syst. 1999;15:545-553.
57.
Bouffet E, Foreman N.Chemotherapy for intracranial ependymomas. Child Nerv Syst. 1999;15:563-570.
58.
Green DM, Thomas PRM, Shochat S.The treatment of Wilms tumor: results of the National Wilms Tumor Studies. Hematol Oncol Clin North Am. 1995;9(6):1267-1274.
59.
Neville HL, Ritchey ML. Wilms’ tumor: overview of National Wilms’ Tumor Study Group results. Urol Clin North Am. 2000;27(3):435-438.
